ATE365718T1 - Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten - Google Patents

Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten

Info

Publication number
ATE365718T1
ATE365718T1 AT98962817T AT98962817T ATE365718T1 AT E365718 T1 ATE365718 T1 AT E365718T1 AT 98962817 T AT98962817 T AT 98962817T AT 98962817 T AT98962817 T AT 98962817T AT E365718 T1 ATE365718 T1 AT E365718T1
Authority
AT
Austria
Prior art keywords
cell proliferation
phenyl
substituted
diseases characterized
treating
Prior art date
Application number
AT98962817T
Other languages
English (en)
Inventor
Carlo Brugnara
Jose Halperin
Rudolf Fluckiger
Emile Bellott
Richard Lombardy
John Clifford
Ying-Duo Gao
Reem Haidar
Eugene Kelleher
Adel Moussa
Yesh Sachdeva
Minghua Sun
Heather Taft
Michael Zeldin
Original Assignee
Harvard College
Childrens Medical Center
Nuchem Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Childrens Medical Center, Nuchem Pharmaceuticals Inc filed Critical Harvard College
Application granted granted Critical
Publication of ATE365718T1 publication Critical patent/ATE365718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT98962817T 1997-11-20 1998-11-20 Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten ATE365718T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97559297A 1997-11-20 1997-11-20

Publications (1)

Publication Number Publication Date
ATE365718T1 true ATE365718T1 (de) 2007-07-15

Family

ID=25523175

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962817T ATE365718T1 (de) 1997-11-20 1998-11-20 Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten

Country Status (14)

Country Link
US (2) US6534497B1 (de)
EP (1) EP1047676B1 (de)
JP (1) JP3790425B2 (de)
CN (1) CN1119334C (de)
AT (1) ATE365718T1 (de)
AU (1) AU749960B2 (de)
BR (1) BR9815617A (de)
CA (1) CA2310748C (de)
DE (1) DE69838002T2 (de)
ES (1) ES2293699T3 (de)
IL (2) IL136225A0 (de)
MX (1) MXPA00005035A (de)
NZ (1) NZ505280A (de)
WO (1) WO1999026929A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992079B2 (en) * 1997-11-20 2006-01-31 President Fellows of Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
CA2778533A1 (en) * 2009-10-22 2011-04-28 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
FR3024778B1 (fr) * 2014-08-05 2021-01-22 Screencell Procede pour le depistage de la drepanocytose et kit pour sa mise en oeuvre

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546165A (en) 1966-02-01 1970-12-08 Du Pont Soluble high-melting,thermally stable linear polyesters
US4006023A (en) 1974-10-07 1977-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare Photographic polymeric composition containing a leuco dye cyanide
US4806685A (en) 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
EP0323740A3 (de) 1987-12-24 1990-12-12 California Biotechnology, Inc. Lineare Analoge von atrialen natriuretischen Peptiden
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
US5358959A (en) 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
WO1996008242A2 (en) 1994-09-16 1996-03-21 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
EP0783303B1 (de) 1994-09-16 2002-11-27 President And Fellows Of Harvard College Verwendung von aromatischen halogenverbindungen zur behandlung der zellproliferation in säugetieren
AU5864796A (en) 1995-05-19 1996-11-29 Sphere Biosystems, Inc. Multiply-substituted fullerenes and methods for their prepar ation and characterization
US6291449B1 (en) * 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
US6063921A (en) * 1997-11-20 2000-05-16 Pharm-Eco Laboratories, Inc. Synthesis of 11-aryl-5,6-dihydro-11H-dibenz[b,e]azepines

Also Published As

Publication number Publication date
AU1797399A (en) 1999-06-15
DE69838002T2 (de) 2008-03-06
CN1119334C (zh) 2003-08-27
EP1047676A4 (de) 2001-11-14
NZ505280A (en) 2003-01-31
MXPA00005035A (es) 2002-10-11
AU749960B2 (en) 2002-07-04
ES2293699T3 (es) 2008-03-16
JP2001524470A (ja) 2001-12-04
US20030191111A1 (en) 2003-10-09
CA2310748A1 (en) 1999-06-03
CA2310748C (en) 2008-07-22
EP1047676A1 (de) 2000-11-02
JP3790425B2 (ja) 2006-06-28
BR9815617A (pt) 2001-10-16
IL136225A0 (en) 2001-05-20
IL136225A (en) 2007-10-31
CN1299350A (zh) 2001-06-13
WO1999026929A1 (en) 1999-06-03
US6534497B1 (en) 2003-03-18
DE69838002D1 (de) 2007-08-09
EP1047676B1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69413789T2 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE273713T1 (de) Fas-antagonist für die prophylaxe oder therapie von gvhd
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69821652D1 (de) Substituierte diphenylindanone, -indane und -indolverbindungen und deren analogue zur verwendung in der prophylaxe und behandlung von krankheiten die sich durch anormale zellproliferation auszeichnen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE55252T1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047676

Country of ref document: EP

REN Ceased due to non-payment of the annual fee